Department of Hematology, Fujian Provincial Key Laboratory of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, PR China.
Future Oncol. 2019 Apr;15(12):1385-1395. doi: 10.2217/fon-2018-0514. Epub 2019 Mar 18.
Despite the progress made in molecular and clinical research, patients with diffuse large B-cell lymphoma (DLBCL) still have a bad prognosis. Recently, chemokines/chemokine receptors have become the subject of interest in relation to DLBCL. Studies have demonstrated the important role of chemokines/chemokine receptors in the communication between DLBCL cells and tumor microenvironment. Studies have also reported the ability of chemokines/chemokine receptors in promoting the proliferation and invasion of DLBCL cells. Here, we summarize the data on mechanisms of DLBCL supporting the involvement of chemokine/chemokine receptor changes. We focus on the available evidence regarding chemokines/chemokine receptors as biomarkers and therapeutic targets for DLBCL.
尽管在分子和临床研究方面取得了进展，但弥漫性大 B 细胞淋巴瘤（DLBCL）患者的预后仍然较差。最近，趋化因子/趋化因子受体已成为与 DLBCL 相关的研究热点。研究表明趋化因子/趋化因子受体在 DLBCL 细胞与肿瘤微环境之间的通讯中发挥重要作用。研究还报告了趋化因子/趋化因子受体促进 DLBCL 细胞增殖和侵袭的能力。在这里，我们总结了支持趋化因子/趋化因子受体改变参与的 DLBCL 机制的数据。我们重点介绍了有关趋化因子/趋化因子受体作为 DLBCL 生物标志物和治疗靶点的现有证据。
